Apnimed, Inc.
corporate_fare Company Profile
Apnimed, Inc. (NASDAQ:APMD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for APMD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for APMD spans 10-Q, 8-K.
Recent high-impact activity:
- Apnimed Q2: $125.9M Net Income Driven by One-Time Gains; Material Weakness in ICFR Disclosed
- Apnimed Q2: FDA Accepts Oxnimbi NDA with Feb 2027 PDUFA Date; $125.9M Net Income
- Apnimed Posts $125.9M Q2 Profit, FDA Accepts NDA for OSA Drug with Feb 2027 PDUFA Date
- Apnimed Closes Upsized IPO at $16, Raises $220.8M with Full Overallotment
- Apnimed IPO Prices at $16 High End, Upsized to $192M, Shares Jump
Short Interest & Short Volume
3.24 days to coverFINRA reported short interest of 879,684 shares in APMD as of the September 15, 2026 settlement, a 55.7% increase from the prior period — about 3.2 days to cover at its recent average daily volume. On October 2, 2026, 33.1% of APMD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for APMD, detected from its recent SEC filings · based on capital-structure filings through 2026-07-31.
IPO Terms Finalized · Pricing Previously Announced
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →